SALL3 and cancer: Histone Deacetylase Inhibitors (HDIs) have been shown to activate silenced genes including CDKN1A, CDKN2A,SALL3, RARb2, TERT and GATA4, in the human cancer cells by active DNA demethylation of their respective promoters [39–41].